Skip to main content
. 2017 Jul 18;18:333. doi: 10.1186/s13063-017-2068-3

Fig. 3.

Fig. 3

FDA reviewer trial interpretation and publication, along with published interpretation of the trial findings, for all novel therapeutic agents in cardiovascular disease and diabetes approved by the US Food and Drug Administration (FDA) between 2005 and 2014, characterized based on the number of trials (a) and the number of patients participating in the trials (b). FDA reviewer trial interpretation as positive, equivocal, or negative